Objective: Multiple myeloma is still one of the incurable hematologic cancers. It
is a common problem of all hematologists to look for new combinations in this malignancy,
that treatment steps are rapidly depleted.
Method: The
cytotoxic activities of carfilzomib, lenalidomide and their combination with
ibrutinib were evaluated using the XTT colorimetric assay on U266B1/BR cells.
Cells were seeded into 96-well plates at a density of 1×104 cells
per well, incubated with various concentrations of ibrutinib, carfilzomib,
lenalidomide and their combinations for 24h and 48h.
Results: In our
study, we found that adding ibrutinib to carfilzomib and lenalidomide
combination in Bortezomib refractory myeloma cell line did not increase
cytotoxicity.
Conclusions: Further clinical and experimental studies are needed
to demonstrate the efficacy of ibrutinib in which many B-cell malignancy has
been demonstrated.
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Medical Science Research Articles |
Authors | |
Publication Date | December 31, 2019 |
Acceptance Date | December 31, 2019 |
Published in Issue | Year 2019Volume: 41 Issue: 4 |